Circulation. Cardiovascular interventions
-
Circ Cardiovasc Interv · Dec 2012
Randomized Controlled Trial Comparative StudyRandomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Ticagrelor and prasugrel provide stronger platelet inhibition compared with clopidogrel. Direct pharmacodynamic comparison between them has not yet been reported in ST-segment-elevation myocardial infarction patients. ⋯ URL: http://www.clinicaltrials.gov. Unique identifier: NCT01463163.
-
Circ Cardiovasc Interv · Dec 2012
Randomized Controlled Trial Multicenter StudyPaclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial.
Peripheral percutaneous transluminal angioplasty is fraught with a substantial risk of restenosis and reintervention. A drug-eluting balloon (DEB) based on a novel coating was compared with uncoated balloons in patients undergoing femoro-popliteal percutaneous transluminal angioplasty. ⋯ URL http://www.clinicaltrials.gov. Unique identifier: NCT01083030.
-
Circ Cardiovasc Interv · Dec 2012
Multicenter StudyPredictors of clinical outcomes in patients with severe aortic stenosis undergoing TAVI: a multistate analysis.
Patients with severe aortic stenosis at increased surgical risk continue to experience compromised long-term survival despite successful transcatheter aortic valve implantation. We used time-related pathways in a multistate analysis to identify predictors of adverse long-term outcome in patients who underwent transcatheter aortic valve implantation. ⋯ A body mass index ≤20 kg/m(2) was identified as a primary predictor of stroke and death after transcatheter aortic valve implantation during long-term follow-up, whereas transapical access emerged as a predictor of kidney injury and ABC. Age >80 years, body mass index ≤20 kg/m(2), prior stroke, and presence of atrial fibrillation at baseline increased the risk of stroke and death after an intercurrent event of ABC.
-
Circ Cardiovasc Interv · Dec 2012
Multicenter StudyPercutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension.
Chronic thromboembolic pulmonary hypertension leads to pulmonary hypertension and right-sided heart failure. The purpose of this study was to investigate the efficacy of percutaneous transluminal pulmonary angioplasty (PTPA) for the treatment of chronic thromboembolic pulmonary hypertension. ⋯ URL: http://www.umin.ac.jp. Unique identifier: UMIN000001572.
-
Circ Cardiovasc Interv · Dec 2012
Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension.
Although balloon pulmonary angioplasty (BPA) for inoperable patients with chronic thromboembolic pulmonary hypertension was first reported over a decade ago, its clinical application has been restricted because of limited efficacy and complications. We have refined the procedure of BPA to maximize its clinical efficacy. ⋯ Our refined BPA procedure improves clinical status and hemodynamics of inoperable patients with chronic thromboembolic pulmonary hypertension, with a low mortality. A refined BPA procedure could be considered as a therapeutic approach for patients with inoperable chronic thromboembolic pulmonary hypertension.